Evaluation of AAV9 gene therapy for SMARD1/CMT2S in different mouse models reveal differences in efficacy dependent on promoter choice.
Multicenter AAV gene therapy studies for SMARD1/CMT2S establish safety and efficacy in multiple animal models and pave the way for initiation of a Phase I/II clinical trial.